In light of these promising reports, ruxolitinib treatment of CNL and aCML patients with CSF3R mutations is currently investigated within clinical trials (NCT02092324). The gene discussed is CSF3R; the disease is atypical chronic myeloid leukemia, BCR-ABL1 negative.